Inhibition of mesothelioma cancer stem-like cells with adenovirus-mediated NK4 gene therapy

International Journal of Cancer

Volumn 137, Issue 2, 2015, Pages 481-490

  Deng, Xu Bin ^a   Xiao, Li ^b   Wu, Yue ^a   Jin, Fang ^b   Mossman, Brooke ^c   Testa, Joseph R ^b   Xiao, Guang Hui ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF VERMONT   (United States)

Author keywords

cancer stem like cells; HGF Met; malignant mesothelioma; NK4; therapy

Indexed keywords

ADENOVIRUS VECTOR; BETA CATENIN; BETA GALACTOSIDASE; NK4 PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; 5-((2,6-DICHLOROBENZYL)SULFONYL)-3-((3,5-DIMETHYL-4-((2-(PYRROLIDIN-1-YLMETHYL)PYRROLIDIN-1-YL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE; HGF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENICITY; CELL VIABILITY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALIGNANT MESOTHELIOMA; MESOTHELIOMA CELL LINE; MOUSE; NK4 GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR INVASION; TUMOR XENOGRAFT; VIRAL GENE THERAPY; ADENOVIRIDAE; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; FLUORESCENCE MICROSCOPY; GENE THERAPY; GENE VECTOR; GENETICS; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; MULTICELLULAR SPHEROID; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; BETA CATENIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; GENETIC THERAPY; GENETIC VECTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; INDOLES; LUNG NEOPLASMS; MESOTHELIOMA; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASTIC STEM CELLS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; SPHEROIDS, CELLULAR; SULFONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929274546     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29391     Document Type: Article

References (49)

1. Zhang YW, Vande Woude GF,. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 2003; 88: 408-17.
2. Christensen JG, Burrows J, Salgia R,. cMet as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005; 225: 1-26.
3. Matsumoto K, Nakamura T,. Mechanisms and significance of bifunctional NK4 in cancer treatment. Biochem Biophys Res Commun 2005; 333: 316-27.
4. Date K, Matsumoto K, Shimura H, et al. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 1997; 420: 1-6.
5. Kuba K, Matsumoto K, Date K, et al. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 2000; 60: 6737-43.
6. Nakabayashi M, Morishita R, Nakagami H, et al. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model. Diabetologia 2003; 46: 115-23.
7. Sakai K, Nakamura T, Matsumoto K,. Angioinhibitory action of NK4 involves impaired extracellular assembly of fibronectin mediated by perlecan-NK4 association. J Biol Chem 2009; 284: 22491-9.
8. Nakamura T, Sakai K, Matsumoto K,. Anti-cancer approach with NK4: bivalent action and mechanisms. Anticancer Agents Med Chem 2010; 10: 36-46.
9. Pass HI, Vogelzang N, Hahn S, et al. Malignant pleural mesothelioma. Curr Probl Cancer 2004; 28: 93-174.
10. Bueno R., Multimodality treatments in the management of malignant pleural mesothelioma: an update. Hematol Oncol Clin North Am 2005; 19: 1089-97, vii.
11. Altomare DA, You H, Xiao GH, et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005; 24: 6080-9.
12. Harvey P, Warn A, Dobbin S, et al. Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology. Br J Cancer 1998; 77: 1052-9.
13. Klominek J, Robért KH, Sundqvist KG,. Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor-like substance. Cancer Res 1993; 53: 4376-82.
14. Harvey P, Clark IM, Jaur MC, et al. Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer 2000; 83: 1147-53.
15. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
16. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006; 66: 9339-44.
17. Gupta PB, Chaffer CL, Weinberg RA,. Cancer stem cells: mirage or reality? Nat Med 2009; 15: 1010-2.
18. Li Y, Li A, Glas M, et al. c-met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci U S A 2011; 108: 9951-6.
19. Hage C, Rausch V, Giese N, et al. The novel c-met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis 2013; 4: e627.
20. Taguchi T, Jhanwar SC, Siegfried JM, et al. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 1993; 53: 4349-55.
21. Reale FR, Griffin TW, Compton JM, et al. Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model. Cancer Res 1987; 47: 3199-205.
22. He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998; 95: 2509-14.
23. Tanno S, Mitsuuchi Y, Altomare DA, et al. AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 2001; 61: 589-93.
24. Poulikakos PI, Xiao GH, Gallagher R, et al. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 2006;25:5960-8.
25. Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253-70.
26. Xiao GH, Jeffers M, Bellacosa A, et al. Anti-apoptotic signaling by hepatocyte growth factor/met via the phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A 2001; 98: 247-52.
27. Friedl P, Wolf K,. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362-74.
28. Sterman DH, Albelda SM,. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 2005; 10: 266-83.
29. Zervos MD, Bizekis C, Pass HI,. Malignant mesothelioma 2008. Curr Opin Pulm Med 2008; 14: 303-9.
30. Ghani FI, Yamazaki H, Iwata S, et al. Identification of cancer stem cell markers in human malignant mesothelioma cells. Biochem Biophys Res Commun 2011; 404: 735-42.
31. Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65: 5506-11.
32. He XC, Yin T, Grindley JC, et al. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet 2007; 39: 189-98.
33. Malanchi I, Peinado H, Kassen D, et al. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 2008; 452: 650-3.
34. Yost C, Torres M, Miller JR, et al. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996; 10: 1443-54.
35. Suzuki Y, Sakai K, Ueki J, et al. Inhibition of met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma. Int J Cancer 2010; 127: 1948-57.
36. Matsumoto K, Nakamura T, Sakai K,. Hepatocyte growth factor and met in tumor biology and therapeutic approach with NK4. Proteomics 2008; 8: 3360-70.
37. Tamase A, Muraguchi T, Naka K, et al. Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc Natl Acad Sci U S A 2009; 106: 17163-8.
38. van Leenders GJ, Sookhlall R, Teubel WJ, et al. Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS One 2011; 6: e26753.
39. Fodde R, Brabletz T,. Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 2007; 19: 150-8.
40. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-72.
41. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-20.
42. Boyer LA, Lee TI, Cole MF, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005; 122: 947-56.
43. Wang J, Rao S, Chu J, et al. A protein interaction network for pluripotency of embryonic stem cells. Nature 2006; 444: 364-8.
44. Jeter CR, Badeaux M, Choy G, et al. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 2009; 27: 993-1005.
45. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-12.
46. Kelly KF, Ng DY, Jayakumaran G, et al. Beta-catenin enhances Oct-4 activity and reinforces pluripotency through a TCF-independent mechanism. Cell Stem Cell 2011; 8: 214-27.
47. Lam H, Patel S, Wong J, et al. Localized decrease of beta-catenin contributes to the differentiation of human embryonic stem cells. Biochem Biophys Res Commun 2008; 372: 601-6.
48. Shulewitz M, Soloviev I, Wu T, et al. Repressor roles for TCF-4 and Sfrp1 in wnt signaling in breast cancer. Oncogene 2006; 25: 4361-9.
49. Shen Z, Yang ZF, Gao Y, et al. The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma. Cancer Res 2008; 68: 404-14.